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Abstract
Purpose The t(14;18) translocation might represent an
intermediate step in the pathogenesis of follicular lymphoma
(FL), one of the most common subtypes of non-Hodgkin
lymphoma. Circulating t(14;18)-positive cells can also be
detected in 30–60 % of healthy individuals at low frequencies.
Some studies found a negative association between repro-
ductive factors or use of menopausal hormone therapy (MHT)
with FL. The objective of this study was to evaluate whether
there is an association between number of frequencies, oral
contraceptive (OC) use, menopausal status and MHT, and
t(14;18) prevalence and frequency in a representative popu-
lation analysis based on an epidemiologic study in the north-
eastern part of Germany.
Methods The analysis is based on results of buffy coat
samples from 1,981 women of the Study of Health in Pomer-
ania (SHIP-0) and data obtained in standardized face-to-face
interviews. For prevalence, odds ratios (OR) and 95 % confi-
dence intervals (CI) were calculated using unconditional
logistic regression. Frequency data were analyzed using neg-
ative binomial regression. The multivariable models included
age, number of pregnancies, menopausal status (premeno-
pausal, natural, medical/surgical menopause), OC use and
MHT as a measure for exogenous hormone exposure use.
Results We found no association between reproductive
history and combined exogenous hormone use on the preva-
lence of circulating t(14;18)-positive cells. Modeling MHT
and OC use separately in a sensitivity analysis, the MHT
parameter yielded statistical significance [OR 1.37 (95 % CI
1.04;1.81)]. t(14;18) frequency was associated with use of OC
[incidence rate ratio (IRR) for ever use 3.18 (95 % CI
1.54;6.54)], current use [IRR 3.86 (1.56;9.54)],[10 years use
[IRR 3.93 (1.67;9.23)] and MHT [restricted to postmeno-
pausal women; IRR 2.63 (95 % CI 1.01;6.85)] in bivariate
age-adjusted analyses. In the multivariable model, medical/
surgical menopause [IRR 2.46 (1.11;5.44)] and the category
ever use of OC and MHT were statistically significant
[IRR 2.41 (1.09;5.33)].
Conclusions Exogenous hormone use might be a risk factor
for t(14;18) frequency rather than for t(14;18) prevalence.
Further research on healthy individuals carrying a t(14;18)
translocation and possible risk factors for malignant lym-
phoma is necessary to determine the additional molecular or
immunological events that have to occur to develop FL.
Keywords t(14;18) translocation  Healthy individuals 
Reproductive history  Exogenous hormone use
Introduction
Non-Hodgkin lymphomas (NHL) comprise a heterogeneous
group of lymphoid malignancies of different morphology and
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genetic characteristics [1]. Causes for common NHL subtypes
remain largely unclear [2]. In epidemiologic studies, risk
factors for NHL were often associated with the immune sys-
tem [3], including HIV infection and immunosuppressive
therapy following organ transplantation [2]. Female hormones
like estrogen, progesterone, and prolactin modulate the
immune system and influence the immune response. Estrogen
decreases plasma levels of interleukin 6, which is a growth
factor for intermediate- and high-grade NHL [4, 5]. During
pregnancy, estrogen and progesterone levels rise [6, 7].
Hence, reproductive factors could explain the lower preva-
lence of NHL in females compared to males [8, 9].
The two most common subtypes of NHL are follicular
lymphomas (FL) with about 20 % and diffuse large B cell
lymphoma (DLBCL) with about 20–35 % of NHL cases
[10–12]. In the USA, for both lymphoma subtypes, higher
incidence rates have been reported in men than in women
[FL: male–female incidence rate ratio (IRR) of 1.2 for
Whites and Asians; IRR 1.6 for Blacks; DLBCL: male–
female IRR of 1.6 for Whites; IRR 1.8 for Blacks; IRR 1.4
for Asians] [13]. However, systematic gender differences
may be restricted to subgroups of the subtypes. Recent data
from Europe show no sex differences or even a slightly
reversed gender ratio of 0.9 for FL [14].
In both FL and DLBCL, high t(14;18) translocation prev-
alence rates have been detected (FL: 70–90 %, DLBCL:
30–50 %) [15–17]. The t(14;18) translocation involves the
immunoglobulin heavy chain (IgH) locus on chromosome
14q32 and the BCL-2 gene on chromosome 18q21 [18]. The
translocation results from an illegitimate V(D)J-recombina-
tion [19] and leads to a constitutive overexpression of the
BCL-2 gene [20]. The resulting BCL-2 protein is involved in a
deregulation of apoptosis [21]. Hence, the t(14;18) translo-
cation might represent an intermediate step in the pathogen-
esis of both NHL subtypes [22, 23]. In animal studies, it was
shown that estrogen treatment reduces early cl? pre-B cells
and IgH gene rearrangements [24]. So estrogen might
decrease the genesis of the t(14;18) translocation.
The t(14;18) translocation can also be detected in
healthy individuals, as first described by Limpens et al.
[25]. In Western countries, about 30–60 % of healthy
persons are carrying this genetic translocation, whereas in
Asia, lower prevalence rates were reported [26–28]. These
results are in line with the low incidence of FL in Japan
[29]. Similar to FL prevalence rates, higher prevalence
rates of the t(14;18) translocation in males compared to
females were observed in healthy individuals [26, 30–32].
Some studies reported negative association between FL
and higher sex hormone levels [33–37]. Changes in estrogen
hormone levels in women occur during and after pregnancy
and menopause and can also be influenced exogenously by
gender-specific drug use like oral contraceptives (OC) or
menopausal hormone replacement therapy (MHT).
Particularly high t(14;18) frequencies in healthy indi-
viduals have been shown to be an early biomarker for FL
[38]. Currently, it is unknown whether there is an associ-
ation between sex-specific hormone levels and the preva-
lence of the t(14;18) translocation in healthy women.
Therefore, the objective of our study was to evaluate a
possible association between both the prevalence and the
frequency of circulating t(14;18)-positive cells with num-
ber of pregnancies and menopausal status as well as gen-
der-specific use of extraneous hormones such as OC and




The Study of Health in Pomerania (SHIP-0) is a repre-
sentative sample of the general population in the north-
eastern part of Germany. Details on the study design,
recruitment and objectives have been published previously
[39]. Briefly, in a two-stage design, a population sample of
7,008 men and women between 20 and 79 years was drawn
randomly using German population registries. After
exclusion of migrated or deceased persons, the net sample
comprised 6,265 individuals. A total of 4,308 individuals
(2,192 females, 2,116 males) participated (response pro-
portion 68.8 %). Written informed consent was obtained
from each participant. Aims of SHIP-0 are to estimate the
prevalence of risk factors, subclinical disorders, and com-
mon clinical diseases as well as their complex associations.
Each participant underwent a comprehensive standard-
ized medical examination. Data collection included a
computer-aided personal face-to-face interview (CAPI) and
a health- and risk factor-related questionnaire to be com-
pleted by the participants. Blood samples were drawn from
the cubital vein according to standardized procedures. The
SHIP-0 study was approved by the Ethics Committee of the
University of Greifswald.
Biosamples
The detection of the t(14;18) translocation in this study
population was described previously [32]. The phenol–
chloroform method was used to isolate DNA from peripheral
blood buffy coat cells (nucleated cells, NC). DNA was stored
at -20 C. The t(14;18) MBR (major break-point region) of
BCL2 was identified by using real-time quantitative PCR.
Wild-type K-RAS gene (reference gene, two copies per
genome) was determined as described previously [40]. For
the t(14;18) assay, five replicates of 1 lg DNA were used.
The t(14;18) MBR PCR assay had a sensitivity of one
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t(14;18)-positive cell in 5 9 105 nucleated cells. A forward
and reverse primer at a concentration of 400 nM, a TaqMan
probe at a concentration of 200 nM, the standard TaqMan
Universal PCR Master Mix (Applied Biosystems, Weiters-
tadt, Germany), and 1.0 lg DNA in a total volume of 50 ll
were contained in the PCR mixture. The 2-min incubation at
50 C to allow for cleavage by Uracil-N-Glycosylase was
followed by incubation at 95 C for 10 min to activate
AmpliTaq Gold. Each PCR cycle included 15 s denaturation
at 95 C, and 1 min of combined annealing/extension at
61 C. Dilution DNA of Karpas 422 cells was used to
establish standard curves for the t(14;18) MBR PCR and for
the K-RAS wild-type PCR. In all PCR experiments, appro-
priate positive and negative controls were included.
For analyzing the influence of reproductive history and
exogenous hormone exposure on prevalence and frequency
of circulating t(14;18)-positive cells, peripheral blood buffy
coat samples from a total of 2,008 (91.6 %) women were
available. A biosample was classified as t(14;18) MBR
positive if C1 of the replicates was PCR positive. None of the
t(14;18) negative samples met our a priori exclusion criterion
of containing less 200,000 K-RAS genome equivalents. To
obtain the t(14;18) frequency, the t(14;18) copies from all
five replicates were summed up and afterward divided by the
sum of tested cells (WT K-RAS copies: 2). The result was
multiplied by 106 to express the frequency as t(14;18)-
positive cells per million NC.
Assessment of reproductive history and exogenous
hormone use
In the standardized computer-assisted personal interview
(CAPI), reproductive history and menopausal status as well
as gender-specific drug use including OC and MHT were
solicited from all female participants in SHIP-0.
The number of pregnancies and the number of births were
categorized as none, one, two, three, and four or more.
Women who responded ‘‘yes’’ to ever having taken OC were
classified as ever users. Women who responded ‘‘no’’ to the
same question were classified as non-users. Based on the
question concerning current use of OC, ever users were
differentiated in current and past users; unknown current
usage was categorized as unknown. Duration of OC use was
categorized to[0 to\5, 5 to\10, and C10 years.
The determination of menopausal status was based on
questions concerning presence of menstrual bleeding (yes/
no), age at last period, and reason of cessation of periods
(natural or medical/surgical). Women aged [40 years ful-
filling the criteria of no menstrual bleeding for at least
1 year prior to the interview were categorized as being
natural menopausal. Women reporting an induced cessa-
tion of menses were categorized as postmenopausal by
medical/surgical reasons. Ever users of MHT were defined
as women who answered ‘‘yes’’ to the following question:
‘‘If you are menopausal, did you ever take any hormones
during the menopausal transition or thereafter, e.g., pat-
ches, tablets, injections?’’ Based on the reported duration
of hormone use, the MHT users were classified in two
categories ([0 to \5, C5 years). Approximate age at
menopause was categorized in tertiles.
In the invitation letters, all participants were asked to
bring their medication packages along and in the interview
prescribed medication over the seven preceding days was
solicited. On the basis of the provided medications, we
were able to identify current MHT users. For an explorative
analysis, we coded the medication according to the ATC
(Anatomical Therapeutic Chemical classification system)-
code subgroup GE03 ‘‘Sex hormones and modulators of the
genital system.’’
Statistical analysis
Statistical analyses were performed with the software
package STATA (Intercooled STATA, STATA/SE 10.1,
StataCorp., Texas, USA). In the descriptive statistics, cate-
gorical data were expressed as percentages; continuous data
were expressed as median and interquartile range (IQR).
Two group comparisons were calculated using Chi-squared
test (v2 test) for categorial data and Mann–Whitney-U test
(MW-test) or Kruskal–Wallis test for continuous data. A
p value \0.05 was considered statistically significant. All
statistical tests were two-sided. Unconditional logistic
regression was used to calculate adjusted odds ratio (OR) and
95 % confidence intervals (CI). For frequency data, negative
binomial regression models were conducted and incidence
rate ratio (IRR) calculated including only t(14;18) positive
women. All models were weighted by the number of tested
cells. The calculation of the likelihood ratio test is not pos-
sible with a simultaneous application of the weight option.
Applying the likelihood ratio test by calculating un-weighted
models yielded that our count data are over-dispersed. Since
the negative binomial regression can be regarded as a gen-
eralization of Poisson regression and should be used in cases
of over-dispersion, we decided to use the negative binomial
regression method as the non-conservative method.
Prior results concern age and sex as influencing factors
both to prevalence and frequency for t(14;18). Since only
women were investigated, we included only age as potential
confounder in the full models. The remaining model vari-
ables operationalize major determinants of hormonal status,
e.g., number of pregnancies, menopausal status including
type of menopause (medical/surgical, natural) and exoge-
nous hormone exposure use (only OC, only MHT, OC and
MHT vs. no exogenous hormone exposure). This opera-
tionalization was selected to reflect our hypotheses of a risk
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due to any exogenous female sex hormone rather than the
effect of any specific source. In a sensitivity analysis, we
provide corresponding results for a model in which ever use
of OC and MHT were modeled as separate variables.
Results
A total of 2,192 women (median: 49, IQR: 36–62 years)
participated in the SHIP-0 cohort. Results of biosamples
were available for 2,008 females. Altogether 17 women
were excluded from this evaluation: four of these declined
to be interviewed and 13 cases reported a history of cancer
at the time of the interview. Missing data of variables
included in the multivariable model yielded to an exclusion
of 23 women.
One thousand nine hundred and sixty-eight women
could be analyzed (89.8 % of the total study population)
for the prevalence of the t(14;18) translocation. Descriptive
characteristics of reproductive history (number of preg-
nancies, number of birth) and exogenous hormone use are
presented in supplementary Table S1.
Prevalence of t(14;18)
In 33.4 % (N = 657) of the women, at least one t(14;18)
copy was detected per 106 cells [prevalence of t(14;18)]. In
older women, the prevalence was higher than in younger
women. The median age of t(14;18) prevalent females was
53 years (IQR: 40–63), whereas the non-prevalent women
had a median age of 46 years (IQR: 34–61) (MW-test:
p \ 0.001). For increasing 10-year age categories, we found
a positive prevalence trend from 18.5 % in the age group
20–29 years up to 43.8 % in the age group 50–59 years,
followed by a 3 % decline in the next age group 60–69 years
down to 35.5 % in the last group of C70 years (Table 1).
Reproductive history and exogenous hormone use as
potential risk factors for the prevalence of the t(14;18)
translocation are described in Table 1. In our study group,
85.3 % of the women had at least one pregnancy. The
maximum number of pregnancies in our sample was 12.
Women reporting two pregnancies represent the largest
group among the t(14;18) prevalent women. Among women
without any pregnancy, 25.3 % were t(14;18) positive,
whereas the prevalence of t(14;18) among women with at
least one pregnancy was 34.8 % (v2 test: p = 0.001). The
prevalence of the t(14;18) translocation increased with
increasing number of pregnancies from 25.3 % in women
with zero pregnancies up to 38.6 % in women with four or
more pregnancies (Table 1). This positive association of the
t(14;18) prevalence with number of pregnancies was
observed in almost the same manner for an increasing
number of births.
Ever users of oral contraceptives had a lower t(14;18)
prevalence rate (31.3 %) than never users (38.1 %) (v2 test:
p = 0.004). Among the postmenopausal women, a signif-
icant higher percentage was t(14;18) positive (39.8 %)
compared to premenopausal women (27.8 %, v2 test:
p \ 0.001). t(14;18) prevalence did not differ for approx-
imate age at menopause (\48 years: 36.6 %, 48 to
[52 years: 44.4 %, C52 years: 39.7 %, v2 test: p = 0.14).
The crude OR showed a positive association of the t(14;18)
prevalence with the number of pregnancies, use of oral
contraceptives and menopausal status, which are mostly
influenced by age (Table 1).
Analyses of hormone replacement therapy (MHT) were
restricted to postmenopausal women only. The t(14;18)
translocation was detected in almost half of the women
(47.3 %) who reported ever use of MHT. The prevalence of
never users was significantly lower (36.0 %, v2 test:
p = 0.002). In bivariate age-adjusted analyses, ever use of
MHT compared to never use yielded a statistically signif-
icant OR of 1.47 (1.09;2.00) as well as MHT use [0 to
\5 years [OR 1.52 (1.07;2.18)].
In the multivariable model, we included age, number of
pregnancies, menopausal status including type of meno-
pause and exogenous hormone use for oral contraceptive
use and menopausal hormone replacement therapy. In this
model, only age showed a significant association with
t(14;18) prevalence with the highest OR of 2.93 in age
group 50–59 years (Table 1).
The risk estimates of age, number of pregnancies and
menopausal status in a logistic regression model including OC
and MHT as separate ever/never variables revealed compara-
ble OR with the model in which both types of use were oper-
ationalized in one variable. The OR for OC use in the sensitivity
model was 0.92 (0.69;1.23) and very similar to the OC/no MHT
[OR 0.94 (0.67;1.32)] category, the OR for MHT use was 1.37
which is slightly lower as the parameter estimate for the cate-
gory no OC/MHT [OR 1.42 (0.93;2.16)], and reached statis-
tical significance (95 % CI 1.04;1.81).
Frequency of t(14;18)
Analyzing frequency data was restricted to t(14;18) positive
women (33.2 %). Supplementary Table S2 provides median
values of t(14;18) frequency per 106 NC for reproductive
factors and exogenous hormone use categorized by age. The
median number of positive NCs for the whole sample was 3.86
per 106 NC (IQR: 1.98-8.27) and increased with increasing
age up to age group 60–69 (median: 4.75) followed by a small
decrease in women aged C70 (median: 4.18). For the number
of pregnancies, we did not observe statistically significant
associations with t(14;18) frequency (Table 2). The age-
adjusted parameter estimates up to three pregnancies were
below one, only for women with more than three pregnancies
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Table 1 Association of t(14;18) prevalence with reproductive history and exogenous hormone use
Total N t(14;18)-negative t(14;18)-positive (%) Crude OR
(95 % CI)
Age-adjusted
OR (95 % CI)
Multivariablea
OR (95 % CI)1,968 1,311 657 (33.2)
Age group
20–29 years 270 220 50 (18.5) 1 – 1
30–39 years 381 271 110 (28.9) 1.78 (1.19;2.66) – 1.72 (1.10;2.68)
40–49 years 370 257 113 (30.5) 2.01 (1.34;3.01) – 1.80 (1.13;2.87)
50–59 years 368 207 161 (43.8) 3.54 (2.39;5.26) – 2.93 (1.66;5.17)
60–69 years 334 198 136 (40.7) 3.05 (2.05;4.56) – 2.57 (1.35;4.89)
C70 years 245 158 87 (35.5) 2.52 (1.64;3.87) – 2.25 (1.12;4.53)
Number of pregnancies
Never pregnant (reference) 289 216 73 (25.3) 1 1 1
C1 1,679 1,095 584 (34.8) 1.51 (1.13;2.04) 1.01 (0.72;1.41) –
1 379 268 111 (29.3) 1.19 (0.82;1.71) 0.90 (0.61;1.33) 0.89 (0.60;1.32)
2 607 398 209 (34.4) 1.43 (1.03;1.99) 0.97 (0.67;1.40) 0.98 (0.67;1.42)
3 348 217 131 (37.6) 1.82 (1.27;2.60) 1.21 (0.80;1.81) 1.23 (0.81;1.85)
C4 345 212 133 (38.6) 1.79 (1.25;2.57) 1.11 (0.74;1.66) 1.14 (0.75;1.72)
Number of births
None (reference) 318 235 83 (26.1) 1 1 –
C1 1,650 1,076 574 (34.8) 1.41 (1.06;1.87) 0.88 (0.64;1.22) –
1 474 336 138 (29.1) 1.07 (0.76;1.50) 0.76 (0.53;1.09) –
2 718 468 250 (34.8) 1.41 (1.03;1.92) 0.91 (0.64;1.30) –
3 274 167 107 (39.1) 1.66 (1.15;2.39) 0.99 (0.65;1.49) –
C4 184 105 79 (42.9) 2.13 (1.42;3.19) 1.21 (0.77;1.91) –
Use of OC
Never (reference) 609 377 232 (38.1) 1 1 –
Ever 1,359 934 425 (31.3) 0.75 (0.61;0.93) 0.99 (0.74;1.31) –
Past 676 479 197 (29.1) 0.83 (0.66;1.04) 0.97 (0.73;1.29) –
Current 403 300 103 (25.6) 0.56 (0.42;0.75) 0.96 (0.65;1.44) –
Past/current unknown 280 155 125 (44.6) 2.05 (0.85;4.90) 1.63 (0.65;4.09) –
Total number of years of OC useb
[0 to \5 years 352 247 105 (29.8) 0.67 (0.50;0.91) 0.89 (0.63;1.26) –
5 to \10 years 335 237 98 (29.3) 0.70 (0.52;0.95) 1.21 (0.82;1.77) –
C10 years 662 442 220 (33.2) 0.83 (0.65;1.06) 1.02 (0.74;1.39) –
Menopausal status
Premenopausal (reference) 1,054 761 293 (27.8) 1 1 1
Postmenopausal 914 550 364 (39.8) 1.67 (1.37;2.05) 0.98 (0.66;1.45) –
Type of menopause
Natural 647 390 257 (39.7) 1.64 (1.32;2.05) 0.93 (0.61;1.42) 0.94 (0.61;1.43)
Medical/surgical 267 160 107 (40.1) 1.76 (1.31;2.36) 1.04 (0.68;1.58) 0.97 (0.63;1.48)
Use of MHTc
Never (reference) 603 386 217 (36.0) 1 1 –
Ever 311 164 147 (47.3) 1.54 (1.15;2.07) 1.47 (1.09;2.00) –
Total number of years of MHT useb,c
[0 to \5 years 188 98 90 (47.9) 1.59 (1.12;2.25) 1.52 (1.07; 2.18) –
C5 years 119 65 54 (45.4) 1.42 (0.93;2.16) 1.34 (0.86;2.07) –
Ever use of OC/MHT
No OC/no MHT (reference) 467 302 165 (25.1) 1 1 1
No OC/MHT 142 745 67 (10.2) 1.53 (1.02;2.29) 1.37 (0.91;2.07) 1.42 (0.93;2.16)
OC/no MHT 1,110 796 314 (47.8) 0.72 (0.57;0.92) 0.96 (0.69;1.34) 0.94 (0.67;1.32)
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the IRR was about 2.1-fold greater compared to never preg-
nant women that means t(14;18) frequency of women C4
pregnancies is over twice as high compared to never pregnant
women. Ever use (IRR 3.18) as well as current (IRR 3.86) and
past use (IRR 3.14) of OC showed a positive association with
t(14;18) frequency as well as OC use C10 years in the
bivariate age-adjusted models (Table 2). Median t(14;18)
frequency did not depend on age at menopause [\48 years:
3.9 (IQR: 1.8-10.0); 48 to \52 years: 4.8 (IQR: 2.9-12.2);
C52 years: 3.9 (IQR: 1.9-8.8), p = 0.06]. The age-adjusted
IRR for women with medical/surgical menopause was
increased [IRR 3.52 (1.25;9.89)]. In the models restricted to
postmenopausal woman, a higher frequency of t(14;18) was
observed among ever users of MHT [IRR 2.63 (1.01;6.85)]
and among short-term users ([0 to \5 years) of MHT
[IRR 4.56 (1.01;20.58)], but not among long-term users
[C5 years, IRR 1.08 (0.50;2.33)] (Table 2).
We did not observe a linear trend in the association
between age and reproductive history and t(14;18) frequency
in the multivariable model (Table 2). No statistically sig-
nificant association was observed for number of pregnancies
(IRR between 0.74 and 0.99). Natural menopause showed no
association with t(14;18) frequency. The IRR for medical/
surgical menopause, however, was significantly increased
[IRR 2.46 (1.11;5.44)]. The multivariable model revealed no
statistically significant IRR for the subgroup of women who
had used only OC or MHT. For the subgroup of women who
had used both IRR were increased 2.41 (1.09;5.33)
(Table 2). In a sensitivity analysis, separate risk estimates
for OC use and MHT were calculated. The IRR for OC use
was statistically significant 2.29 (1.31;4.00), but not for
MHT [IRR 1.02 (0.65;1.61)].
Discussion
The biologic mechanisms for developing NHL are currently
unclear. The t(14;18) translocation is the genetic hallmark
for FL and DLBCL, two of the most common subtypes of
NHL. The translocation can be found in 70–90 % of FL
cases and in 30–50 % of DLBCL cases [15–17]. In Western
countries, this mutation is detectable in about 30–60 % of
healthy individuals [26–28]. Prevalence and frequency of
t(14;18)-positive cells in healthy individuals are associated
with known FL risk factors like increasing age and male sex
[27, 28, 32, 41]. Roulland et al. [38] published very recently
that the presence of t(14;18)-positive cells in healthy indi-
viduals is associated with an increased risk for FL and that
these cells represent true lymphoma precursors which are
clonally related to the clinically overt lymphoma that man-
ifests at a later time point.
Epidemiologic observations link reproductive factors
and gender-specific hormone use with risk of NHL [1, 9,
33]. Estrogen seems to be a protective factor for FL and
DLBCL.
To the best of our knowledge, this is the first study
investigating a possible association between circulating
t(14;18)-positive cells and reproductive factors and exoge-
nous hormone use in healthy females. In bivariate analyses,
we found some positive associations between the t(14;18)
prevalence and MHT use (ever vs. never, years of use). In
the multivariable model, only age remains a statistically
significant predictor showing a positive association with the
t(14;18) prevalence. In a sensitivity analysis including OC
use and MHT as separate variables in the model, an
increased OR for MHT was observed. Restricting the mul-
tivariable model to postmenopausal women did not change
the risk estimates significantly (data not shown).
Analyzing t(14;18) frequency in the multivariable
model, the parameter estimates for age are less consistent
and only age group 60–69 was associated with a signifi-
cantly increased frequency (IRR 3.67). A positive associ-
ation of medical/surgical menopause was observed
(IRR 2.46). For ever use of both OC and MHT, the IRR of
2.41 was statistically significant. Restricting the multivar-
iable model to postmenopausal women yielded comparable
risk estimates (data not shown). A sensitivity analysis of
OC use and MHT as separate variables in the model
including all women yielded a statistically significant IRR
for history of OC use. The separate parameter estimate for
MHT was not statistically significant. Approximately three
times as many women have ever taken OC compared to
MHT (Table 1). Compared to MHT, OCs were taken on
average at considerably younger ages. Based on these
Table 1 continued
Total N t(14;18)-negative t(14;18)-positive (%) Crude OR
(95 % CI)
Age-adjusted
OR (95 % CI)
Multivariablea
OR (95 % CI)1,968 1,311 657 (33.2)
OC/MHT 249 138 111 (16.9) 1.46 (1.05;2.03) 1.30 (0.89;1.90) 1.26 (0.86;1.86)
a Multivariable model including age, number of pregnancies, type of menopause, and exogenous hormone exposure use
b Do not sum up to 100 % due to missing data
c Restricted to menopausal women
OC, oral contraceptive; MHT, menopausal hormone therapy; OR, odds ratio (method: logistic regression); 95 % CI, 95 % confidence interval
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Table 2 Association of t(14;18) frequency with reproductive history and exogenous hormone use
Number (N = 657) Median (first; third quartile)
of t(14;18) frequency




IRR (95 % CI)
Multivariablea
IRR (95 % CI)
Age group
20–29 years 50 3.15 (1.77;5.03) 1 – 1
30–39 years 110 3.72 (1.99;5.16) 0.94 (0.34;2.41) – 1.08 (0.43;2.72)
40–49 years 113 3.13 (1.93;6.25) 1.23 (0.47;3.22) – 1.43 (0.55;3.70)
50–59 years 161 3.97 (1.99;8.58) 0.97 (0.40;2.32) – 1.15 (0.44;3.03)
60–69 years 136 4.75 (2.27;10.12) 6.35 (1.06;37.96) – 3.67 (1.10;12.27)
C70 years 87 4.18 (1.90;10.01) 1.15 (0.39;3.37) – 2.19 (0.65;7.34)
Number of pregnancies
Never pregnant (reference) 73 3.14 (1.79;5.63) 1 1 1
C1 584 3.94 (1.99;8.38) 2.13 (0.66;6.91) 0.98 (0.51;1.90) –
1 111 3.46 (1.83;6.80) 1.03 (0.47;2.26) 0.95 (0.44;2.05) 0.91 (0.43;1.94)
2 209 4.20 (2.11;9.08) 1.10 (0.54;2.24) 0.86 (0.44;1.68) 0.85 (0.44;1.64)
3 131 3.98 (2.43;7.99) 1.05 (0.48;2.28) 0.87 (0.40;1.93) 0.74 (0.35;1.55)
C4 133 3.86 (1.92;9.11) 5.74 (1.00;33.11) 2.13 (0.74;6.14) 0.99 (0.48;2.08)
Number of births
None (reference) 83 3.14 (1.76;5.63) 1 1 –
C1 574 3.95 (1.99;8.41) 1.84 (0.55;6.14) 0.82 (0.41;1.65) –
1 138 3.63 (1.93;8.16) 0.87 (0.42;1.82) 0.81 (0.38;1.73) –
2 250 4.04 (2.03;9.01) 0.91 (0.45;1.84) 0.71 (0.35;1.45) –
3 107 3.97 (2.44;7.37) 6.03 (1.03;35.26) 2.26 (0.68;7.53) –
C4 79 3.86 (1.76;9.13) 0.68 (0.32;1.45) 0.38 (0.18;0.80) –
Use of OC
Never (reference) 232 4.24 (2.12;9.19) 1 1 –
Ever 425 3.65 (1.92;6.91) 2.54 (0.74;8.68) 3.18 (1.54;6.54) –
Past 197 2.96 (1.81;5.61) 3.01 (0.75;12.11) 3.14 (1.50;6.59) –
Current 103 3.86 (2.22;6.25) 1.29 (0.67;2.48) 3.86 (1.56;9.54) –
Past/current unknown 125 4.18 (1.83;9.13) 0.68 (0.32;1.45) 1.70 (0.74;3.90) –
Total number of years of OC useb
[0 to \5 years 105 4.05 (1.92;8.29) 1.00 (0.53;1.88) 2.05 (0.96;4.38) –
5 to \10 years 98 2.79 (1.80;5.75) 0.93 (0.49;1.74) 2.05 (1.01;4.18) –
C10 years 220 3.82 (2.00;7.10) 3.99 (0.92;17.38) 3.93 (1.67;9.23) –
Menopausal status
Premenopausal (reference) 293 3.39 (1.91;5.33) 1 1 1
Postmenopausal 364 4.29 (2.05;9.49) 2.84 (0.80;10.18) 1.16 (0.71;1.90) –
Type of menopause
Natural 257 4.17 (2.03;8.99) 0.89 (0.61;1.29) 0.68 (0.38;1.24) 0.68 (0.38;1.23)
Medical/surgical 107 4.77 (2.10;11.27) 7.37 (1.48;36.58) 3.52 (1.25;9.89) 2.46 (1.11;5.44)
Use of MHTc
Never (reference) 217 4.18 (2.05;8.46) 1 1 –
Ever 147 4.73 (2.09;12.05) 4.76 (0.89;25.49) 2.63 (1.01;6.85) –
Total number of years of MHT useb,c
[0 to \5 years 90 4.44 (2.17;12.23) 7.25 (1.20;43.77) 4.56 (1.01;20.58) –
C5 years 54 5.73 (1.99;11.93) 0.90 (0.45;1.80) 1.08 (0.50;2.33) –
Ever use of OC/MHT
No OC/no MHT (reference) 165 4.09 (2.00;8.34) 1 1 1
No OC/MHT 67 5.49 (2.60;12.23) 0.63 (0.35;1.12) 0.79 (0.44;1.43) 0.68 (0.40;1.16)
OC/no MHT 314 3.48 (1.92;6.04) 0.97 (0.54;1.73) 1.93 (0.95;3.93) 1.77 (0.94;3.33)
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results, it could be speculated that exposure at younger
ages may have a positive impact on t(14;18), while it does
not affect prevalence.
Our multivariable analyses revealed no statistically
significant parameter estimates for number of pregnancies,
neither on prevalence nor on frequency. However, we
observed decreased risks on t(14;18) frequency for women
with at least one pregnancy. Several studies reported also a
negative association between number of pregnancies and
risk of DLBCL or FL [33–35, 42]. In line with this, two
other studies showed an enhanced risk of NHL for null and
low parity [43, 44].
Our results of the positive association between ever use
of OC and t(14;18) frequency are consistent with Costas
et al. [45] who reported slightly increased risks of FL
(OR 1.49) and DLBCL (OR 1.28) with ever use of OC.
Other studies reported inconsistent risks of NHL or its
subtypes FL and DLBCL with use of OC [34, 46, 47]. This
variation, however, might at least partly be attributable to
low sample sizes.
Type of menopause was investigated by Morton et al.
[9] in the National Institutes of Health-AARP Diet and
Health Study cohort. The authors observed increased risks
of women with surgical menopause versus women being
natural menopausal (aged 50–54 years) for FL and
DLBCL which is in line with our t(14;18) frequency
results.
Inconclusive findings were published for MHT use.
Among postmenopausal women, Mildon et al. [36] repor-
ted a decreased but statistically not significant risk of MHT
users compared to non-users for FL (OR 0.6) and DLBCL
(OR 0.7). Similar results were presented in a pooled ana-
lysis of the InterLymph case–control study for ever versus
never MHT users with an OR of 0.82 for FL and an OR of
0.66 for DCBCL [37]. However, data from the California
Teachers Study show elevated but not significant risks for
ever versus never MHT use (FL: RR = 1.57; DLBCL:
RR = 1.15) [47]. These results are in line with our
bivariate age-adjusted findings restricted to postmeno-
pausal women. Ever use of MHT compared to never use
yielded a statistically significant OR of 1.47 in a prevalence
analysis and a statistically significant IRR of 2.63 in a
frequency analysis.
Cerhan et al. [48] compared current and former users
with never users of MHT analyzing data from the Iowa
Women’s Health Study cohort and found significantly
increased risk estimates for FL (RR current: 3.3; RR for-
mer: 2.6), but no association for diffuse NHL. The SHIP
interview did not differentiate between current use and
former use of MHT. Based on the 7-day medication, we
identified 13.7 % current MHT users among the 914
postmenopausal women with GE03 medication based on
ATC classification. 44.8 % of these current users are car-
rying the t(14;18) translocation. The prevalence among
women currently not taking any menopausal therapy is
slightly lower (39.0 %) (p = 0.24). t(14;18) frequency of
women currently applying MHT is not different compared
to women who are not current users [4.47 (1.83;8.52) vs.
4.24 (2.10;10.11) per 106 NC, p = 0.75].
Analyzing only the subgroup of current MHT users, we
were able to differentiate estrogen, estrogen - progestin,
and progestin users. We did not observe a difference of
t(14;18) prevalence and frequency of women with current
use of only estrogen versus estrogen ? progestin as MHT
[41 % vs. 46 %, p = 0.63; 3.58 (1.58;7.83) vs. 5.22
(2,31;8.61) per 106 NC; p = 0.20]. The t(14;18) prevalence
of MHT containing progestin only was 60 %, but this
finding is limited to a small sample size (N = 5). Morton
et al. reported similar risks for different types of MHT in
FL and DLBCL patients [9]. Data from the California
Teachers Study and the Iowa Women’s Health Study
showed also increased risk estimates with duration of MHT
use compared to never users, although sample sizes are
often small [47, 48]. In bivariate age-adjusted analyses, we
observed a statistically significantly increased risk for
MHT use[0 to\5 years for prevalence (OR 1.52) as well
Table 2 continued
Number (N = 657) Median (first; third quartile)
of t(14;18) frequency




IRR (95 % CI)
Multivariablea
IRR (95 % CI)
OC/MHT 111 3.91 (1.83;9.11) 5.96 (1.03;34.42) 4.55 (1.33;15.53) 2.41 (1.09;5.33)
Example of interpreting IRR. (1) age-adjusted IRR of postmenopausal women is 1.16; t(14;18) frequency is 16 % higher compared to pre-
menopausal women, (2) age-adjusted IRR of women with 1 pregnancy is 0.95; t(14;18) frequency is 5 % less high compared to never pregnant
women
a Multivarible model including age, number of pregnancies, type of menopause, and exogenous hormone exposure use
b Do not sum up to 100 % due to missing data
c Restricted to menopausal women
OC, oral contraceptive; MHT, menopausal hormone therapy; IRR, incidence rate ratio (method: negative binomial regression); 95 % CI, 95 %
confidence interval; NC, nucleated cells
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as for frequency (IRR 4.56) but not for MHT use C5 years.
We cannot completely exclude a possible bias due to a
changing pattern of MHT use over time (e.g., dose and/or
application pattern) or with respect to the application of
different formulation/types of MHT.
Heterogeneous results in published risk estimates con-
cerning NHL and hormone-associated factors in women
might be attributable to a lack of differentiation of the NHL
subtypes in many analyses. Only very few studies assessed
possible risk factors separately for specific NHL subtypes.
Other influencing factors include study setting, selection of
confounding factors, small sample sizes, limited age range
of participants, formulation of exogenous hormones, and
duration of the application.
We observed a curvilinear association of age with both
translocation prevalence and frequency. This observation is
consistent with the age-specific incidence of FL. The median
age at diagnosis for FL is about 65 years [49], which is
comparable to the age with the highest t(14;18) prevalence
and frequency in our study group. It is, however, unclear,
why in older ages t(14;18) prevalence and frequency
decline, while lymphoma incidence continues to increase.
Our analysis is based on the baseline examination of a
population-based cohort, which is characterized by a high
life-time prevalence of OC and MHT use [50]. The popu-
lation-based sampling together with a high response pro-
portion compared to other German cohorts [51] limit major
selection bias and increases the external validity of these
results. The study size of well-characterized women redu-
ces statistical uncertainty. Information on reproductive
history (number of pregnancies, parity) and hormone use
(OC, MHT) was collected based on a standardized personal
face-to-face interview (CAPI) conducted in designated
study centers with each study participant. Reliability of
self-reporting of reproductive factors and women health
has been shown [52].
We were not able to evaluate the number of years after last
birth, the age at menarche, the number of years of ovulation,
and sex of the children born because the respective data were
not collected. Furthermore, we did not consider hormonal
influences of non-oral contraceptives like hormone injection
or patches. In Germany, however, these methods play a minor
role in contraception [53, 54], so we do not assume a con-
siderable bias. Prescribed medication was solicited over the
seven days preceding the interview. In the invitation letters,
participants were asked to bring their medication packages
along, and most did so. Data about calendar year or age of first/
last OC medication, duration or pattern of application were not
collected. Therefore, we were neither able to consider changes
in OC formulation over the lifetime of women nor to perform a
dose–response analysis.
In epidemiologic studies, no standardized definition for
menopausal status exists [55, 56]. Due to (1) a variety of
different definitions, (2) the complex processes of the
transition from pre- to postmenopausal status, which can
occur over several years or (3) a changing symptomology
because of the use of MHT or hysterectomy, it is not trivial
to characterize the menopausal status of women in popu-
lation-based studies. We cannot exclude a potential mis-
classification of some of the women regarding their
menopausal status. We used information on menstrual
bleeding, which is difficult to evaluate in women who are
taking MHT or had a hysterectomy or are in the peri-
menopausal status. Nevertheless, we only had 1.9 % of
women aged C40 years with an uncertain menopausal
status. Because of this small percentage, we assume no
major bias, if any.
The t(14;18) translocation is the genetic hallmark for FL
and DLBCL. The complex relationship by which exoge-
nous hormone use like OC or MHT may lead to both NHL
subtypes is not fully understood. It is known that sex
hormones influence the B cell development [57]. Kane
et al. indicate that estrogen at physiological levels sup-
presses the humoral response, whereas the exogenous
estrogen from OC increases the humoral response. This
leads to a reduction of IFN-c and the enhancement of IL-6
and IL-10, which together may induce an increase of the
number of B lymphocyte subpopulations and estrogen-
induced expression of the BCL-2 gene which reduces
apoptosis of B cells [42]. Both mechanisms could support
the persistence of cells carrying the t(14;18) translocation
over longer periods of time, which would explain the
positive associations between t(14;18) frequency and use of
OC and MHT observed in this study.
Conclusion
To our knowledge, this is the first study analyzing t(14;18)
prevalence and frequency data with regard to female
reproductive history and exogenous hormone use in a
population-based sample of healthy women.
In summary, we found a strong curvilinear trend of age
on the prevalence of the t(14;18) translocation with a
maximum among the 50–59 old and lower prevalence for
the younger and older women, respectively. Our results
suggest no relevant influence of number of pregnancies or
type of menopause on the prevalence of the t(14;18)
translocation.
For t(14;18) frequency, significant associations were
observed with age-adjusted ever use of OC, and especially
among current and long-term users. In the multivariable model,
medical/surgical menopause and the category ever use of both
OC and MHT showed significantly increased risk estimates.
Our results suggest that exogenous hormone use is a risk
factor for t(14;18) frequency rather than for t(14;18)
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prevalence. In our study, some 80 % of all women prevalent
for t(14;18) had only one clone. Only one woman had four
different clones, which was the highest number of different
clones observed. Hence exogenous hormone use might
rather act on the expansion of existing clones than causing
de novo mutations. Since it has been shown that the detec-
tion of t(14;18)-positive cells in healthy individuals repre-
sents a biomarker of increased FL risk [38], future research
should aim at defining which individuals are at highest risk
and which additional molecular or immunological events
ultimately lead to the transformation of a t(14;18)-positive
cell into a fully malignant lymphoma clone. A promising
starting point might be a systematic prospective follow-up of
healthy individuals carrying a t(14;18) translocation as a
possible FL precursor in the SHIP-cohort. In a prospective
approach, a variety of NHL risk factors can be monitored
and their respective contribution toward developing clinical
FL or DLBCL can be quantified.
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